This presentation contains certain forward-looking statements regarding the business of Mirati Therapeutics, Inc.
(“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs,
development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation
adagrasib (MRTX849), sitravatinib, MRTX1133 and MRTX1719 is a forward-looking statement and should be
considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges
inherent in the process of discovering, developing and commercialization of new drug products that are safe and
effective for use as human therapeutics, and in the endeavor of building a business around such drugs.
相关推荐
热门下载
推荐
快速链接
热门标签
关注我们
扫码关注我们
了解更多相关信息